ivWatch Sensor: Device Validation for Infiltrated Tissues
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04064229 |
Recruitment Status :
Completed
First Posted : August 21, 2019
Results First Posted : June 24, 2022
Last Update Posted : June 24, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Infiltration of Peripheral IV Therapy | Device: ivWatch Model 400 with SmartTouch Sensor Device: ivWatch Model 400 with Fiber Optic Sensor | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 99 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | ivWatch Sensor: Device Validation for Infiltrated Tissues |
Actual Study Start Date : | April 3, 2019 |
Actual Primary Completion Date : | April 9, 2019 |
Actual Study Completion Date : | April 9, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: Infiltrated Tissue
The ivWatch Model 400 sensors monitored an IV site during the infiltration of 10 mL of isotonic saline solution. IV sites were placed in the forearm and the dorsal aspect of the hand. The rate of the infiltration ranged between 5 mL/hr to 150 mL/hr.
|
Device: ivWatch Model 400 with SmartTouch Sensor
The ivWatch Model 400 with SmartTouch Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected. Device: ivWatch Model 400 with Fiber Optic Sensor The ivWatch Model 400 with Fiber Optic Sensor monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected. |
- Red Notification Sensitivity to Infiltrated Tissues [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]The ratio of the number of infiltrated IV sites where the ivWatch Model 400 device issued a red notification to the total number of infiltrated IV sites in the study. All infiltrations were limited to 10 mL of isotonic saline solution.
- Yellow Notification Sensitivity to Infiltrated Tissues [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]The ratio of the number of infiltrated IV sites where the ivWatch Model 400 device issued a yellow notification to the total number of infiltrated IV sites in the study. All infiltrations were limited to 10 mL of isotonic saline solution.
- Infiltrated Volume When Red Notification Issued [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]The amount of infiltrated isotonic saline solution when the red notification was issued by the ivWatch Model 400 device.
- Infiltrated Volume When Yellow Notification Issued [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]The amount of infiltrated isotonic saline solution when the yellow notification was issued by the ivWatch Model 400 device.
- Significant Skin Irritation or Disruption to Skin Integrity [ Time Frame: After each participant has been infiltrated, an expected average of 1 hour ]The number of IV sites that indicated significant skin irritation or disruption to skin integrity assessed at the end of the study.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Informed Consent
- Pass health screen by clinician
- 18 years or older
Exclusion Criteria:
- Fail health screen

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04064229
United States, Virginia | |
ivWatch, LLC | |
Williamsburg, Virginia, United States, 23185 |
Documents provided by ivWatch, LLC:
Responsible Party: | ivWatch, LLC |
ClinicalTrials.gov Identifier: | NCT04064229 |
Other Study ID Numbers: |
IVW-CLR-CS27-400 |
First Posted: | August 21, 2019 Key Record Dates |
Results First Posted: | June 24, 2022 |
Last Update Posted: | June 24, 2022 |
Last Verified: | May 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Product Manufactured in and Exported from the U.S.: | No |